3 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Induction therapy: new trials by email Literature Review of Induction therapy trials Research Report on Induction therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy - Squamous Cell Carcinoma of the Anal Canal | Phase 2 | Not yet recruiting | Wang Xin | 34 | 2026-09-20 | 2026-09-08 |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel Cilta-cel, Cyclophosphamide, Induction therapy - Multiple Myeloma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 60 | 2025-10-03 | 2026-11-03 |
| Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial Induction Therapy, Maintenance Therapy - Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2025-09-04 | 2025-12-18 |
| Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC Induction therapy - Metastatic Breast Cancer | Phase 2 | Recruiting | Japan Breast Cancer Research Group | 106 | 2024-09-13 | 2025-01-30 |
| RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC RT 50 Gy, RT 54 GY, RT 60 GY - Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2022-06-14 | 2022-07-07 | |
| Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer Chemotherapy, Radiation - Pancreatic Cancer | Phase 2 | Unknown | Campus Bio-Medico University | 50 | 2016-07-01 | 2022-06-01 |
| Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer Radiation, Chemotherapy - Pancreatic Cancer | Phase 2 | Completed | Campus Bio-Medico University | 41 | 2013-03-01 | 2016-12-07 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate - Estrogen Receptor Positive, HER2/Neu Negative | Phase 2 | Terminated | National Cancer Institute (NCI) | 16 | 2013-01-01 | 2018-05-08 |
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer Induction therapy - Breast Cancer | Phase 2 / Phase 3 | Completed | Women's Cancer Study Group GmbH | 4936 | 2012-05-01 | 2025-02-27 |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer Pentostatin, Sirolimus, Cyclophosphamide - Renal Cell Carcinoma, Graft-Versus-Host Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2008-03-01 | 2017-09-29 |
Breast Neoplasms (3) · Pancreatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Graft vs Host Disease (1) · Kidney Neoplasms (1) · Multiple Myeloma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Campus Bio-Medico University (2) · National Cancer Institute (NCI) (2) · Icahn School of Medicine at Mount Sinai (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Janssen Research & Development, LLC (1) · Japan Breast Cancer Research Group (1) · Wang Xin (1) · Women's Cancer Study Group GmbH (1)
United States (4) · China (2) · Australia (1) · Germany (1) · Japan (1) · Spain (1)
Cynthia Ma (1) · Daniel H Fowler, M.D. (1) · Lucio Trodella, MD (1) · Marshall Posner, MD (1) · Michele Fiore, MD (1) · Nadia Harbeck, Prof. Dr. (1) · Shuhua Yi, Dr (1) · Ulrike Nitz, Prof. Dr. (1)
2016 (1), 2025 (1), N01CM00071 (1), N01CM00099 (1), P30CA015083 (1)